[{"id":"006154e1-1580-45ba-ae5b-88d5b8c35fa2","acronym":"BIONIKK","url":"https://clinicaltrials.gov/study/NCT02960906","created_at":"2021-03-03T14:55:07.666Z","updated_at":"2024-07-02T16:36:31.235Z","phase":"Phase 2","brief_title":"A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer","source_id_and_acronym":"NCT02960906 - BIONIKK","lead_sponsor":"Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie","biomarkers":" CD8 • PD-1 • LAG3 • TFE3 • TFEB","pipe":" | ","alterations":" TFEB translocation","tags":["CD8 • PD-1 • LAG3 • TFE3 • TFEB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFEB translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • pazopanib"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 02/15/2021","primary_completion_date":" 02/15/2021","study_txt":" Completion: 02/15/2021","study_completion_date":" 02/15/2021","last_update_posted":"2021-04-26"}]